|Articles|November 1, 2016
Schulman IRB to Launch COR Division
Schulman IRB will launch its new Central Oncology Review (COR) division this month.
Advertisement
Schulman IRB will launch its new Central Oncology Review (COR) division this month. The COR will feature a roster of oncology industry leaders, academics and distinguished scientists, each with a background in managing specialized oncology research.
Read the full release
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
ACT Brief: Real-Time Evidence Generation, Protocol Digitization, and Decentralized Trial Flexibility
2
Achieving Clinical Trial Success with Three Key Elements of eCOA User Acceptance Testing
3
ACT Brief: Real-Time Data Harmonization Infrastructure, Modern Trial Payments, and SCLC Drug Confirmatory Failure
4
Tapping the Global Potential of China’s Biotech Surge
5